Posted 1 month ago

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

ClinicalTrials.gov ID NCT06246110

Protocol number EIK1001-005

Sponsor Eikon Therapeutics